JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

Sponsor
RenJi Hospital
Study ID
NCT06567080
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Autoimmune Diseases
  • B-cell Tumors
  • Large B-cell Lymphoma
  • Lupus Erythematosus, Systemic

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • JWCAR201 — BIOLOGICAL
    JWCAR201 is a autologous CAR-T targeting CD19/CD20

Study Details

JWCAR201 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR201 in patients with B cell driven hematology malignancy and autoimmune diseases

Key Dates

First listed
Aug 22, 2024
Start date
Sep 30, 2024
Status verified
Aug 2024
Primary completion
Sep 30, 2025
Completion
Mar 31, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: JWCAR201 arm
    Subjects in this arm will receive intervention with JWCAR201

Primary Outcome Measure

the rate of Dose Limiting Toxicity events [ Time Frame: 28 days ]

Central Contacts

Related Studies